<DOC>
	<DOCNO>NCT00002973</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Hyperthermia therapy kill tumor cell heat several degree body temperature . Combining hyperthermia chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness melphalan whole-body hyperthermia treat patient advanced melanoma .</brief_summary>
	<brief_title>Melphalan Whole-Body Hyperthermia Treating Patients With Advanced Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate combination 41.8 degree Celsius whole body hyperthermia ( WBH ) melphalan ( L-PAM ) patient advanced melanoma . II . Assess efficacy combination therapy . III . Assess clinical toxicity WBH L-PAM patient . IV . Obtain pilot data effect WBH L-PAM cytokine induction patient . OUTLINE : The combination whole body hyperthermia ( WBH ) melphalan ( L-PAM ) administer week 1 . The infusion L-PAM administer constant rate approximately 10 minute , begin 20 minute achieve target temperature 41.8 degree Celsius esophageal axillary temperature probe . WBH continue additional 40 minute total 60 minute . On week 5 6 , patient receive another combination WBH L-PAM . Disease status reevaluate least every 2 course . Patients without progressive disease continue therapy WBH L-PAM every 4 week maximum 6 course . PROJECTED ACCRUAL : Approximately 34 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced melanoma beyond hope surgical cure metastatic disease Tumors must refractory know form effective therapy No CNS tumor involvement No major liver involvement ( 33 % replacement liver tumor ) PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC great 3,000/mm3 Absolute granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Alkaline phosphatase great 3 time normal SGOT great 3 time normal Protein le 15 % low limit normal Renal : BUN le 30 mg/dL Creatinine le 1.5 mg/dL OR Creatinine clearance le 60 mL/min Calcium great 11.0 mg/dL Sodium 130150 mEq/L Potassium 3.05.0 mg/dL Cardiovascular : No organic heart disease , include : coronary artery disease history angina history dysrhythmia require ongoing medical intervention uncontrolled hypertension patient require beta blocker Neurologic : No moderate severe peripheral neuropathy No history severe emotional instability psychiatric history Pulmonary : FEV1 least 60 % predict Maximum voluntary volume least 60 % predict Partial pressure oxygen least 60 OR Oxygen saturation least 90 % Other : No history secondary primary cancer conceivably could active No active nonmalignant gastric and/or duodenal ulcer No serious infection require hospitalization within previous 14 day No history hepatitis relate general anesthesia No history allergy lidocaine relate compound No development malignant hyperthermia general anesthesia No unexplained persistent fever Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since biologic therapy Chemotherapy : At least 8 week since nitrosoureas ( e.g. , lomustine , carmustine , mitomycin ) At least 4 week since chemotherapy Recovered toxic effect No concurrent chemotherapy Endocrine therapy : At least 4 week since endocrine therapy No concurrent hormonal therapy Radiotherapy : At least 4 week since radiotherapy No prior irradiation 25 % marrow Surgery : Not specify Other : No concurrent nonsteroidal antiinflammatory agent aspirin</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>